Hutchmed to Host Savolitinib Webcast November 5
The company will discuss recent Phase III clinical trial data for the cancer drug.
Updated on Oct. 30, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies provide full transparency regarding clinical trial data results?
Hutchmed will host an expert insights webcast on November 5, 2026, to review clinical trial data for the cancer drug savolitinib. The discussion follows the recent presentation of Phase III results at the ESMO Congress 2026.
Why it matters
The webcast provides analysts and investors with a detailed look at the clinical efficacy of savolitinib in treating patients with specific lung cancer markers. It serves as an update on the company's broader efforts to expand therapeutic options for patients with MET-driven diseases.
The SAFFRON phase III trial enrolled 338 patients across 29 countries, while the SANOVO study randomized 326 patients. Results from the SAFFRON trial showing improvements in progression-free and overall survival were reported in August 2026.
The players
Hutchmed
This biopharmaceutical company focuses on the discovery and development of targeted therapies for oncology and immunology.
Yi-Long Wu
He is a professor and medical researcher who will lead the presentation on the SANOVO study results.
Weiguo Su
He serves as a leadership figure for the scientific team discussing the clinical findings of the savolitinib trials.
The details
Professor Yi-Long Wu and Dr. Weiguo Su will lead the webcast, which focuses on findings from the SANOVO and SAFFRON studies. The SANOVO trial evaluated savolitinib combined with Tagrisso, utilizing selection criteria based on MET level cut-offs identified in the earlier SAVANNAH phase II study.
Timeline
August 2026: SAFFRON phase III trial reported positive clinical results.
November 5, 2026: Hutchmed will host an expert insights webcast.
The Big Picture
This development follows the precedent set by the SAVANNAH phase II trial which established the MET level cut-offs used to refine patient selection for current Phase III efficacy testing. The trial design reflects a broader shift toward biomarker-driven precision oncology.
Savolitinib is currently marketed in China as Orpathys and has received temporary authorization in Switzerland for specific patient groups. These trial results provide critical evidence that may influence future treatment accessibility for patients with MET overexpression or amplification.
The takeaway
Advancements in targeted therapies like savolitinib demonstrate the clinical value of stratifying patients based on genetic markers. Patients and providers should monitor regional drug authorizations as phase III data continues to validate these precision approaches.
Further reading
Find more information on the latest research in our Cancer section.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you trust that pharmaceutical companies provide full transparency regarding clinical trial data results?
